No connection

Search Results

LUCD

BEARISH
$1.28 Live
Lucid Diagnostics Inc. · NASDAQ
Target $4.1 (+220.3%)
$0.95 52W Range $1.7
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026
Market cap
$218.06M
P/E
N/A
ROE
-710.6%
Profit margin
N/A
Debt/Equity
2.36
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
LUCD exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness in profitability, leverage, and operating efficiency. The company suffers from catastrophic operating margins (-931.58%) and negative shareholder equity (P/B of -3.87), suggesting a precarious balance sheet. While revenue growth remains positive at 25.6%, there is a massive disconnect between the fundamental decay and the 'Strong Buy' analyst consensus. The valuation is unjustifiable on a data-driven basis, with a Price/Sales ratio of 46.34 for a company consistently missing earnings estimates.

Key Strengths

Consistent year-over-year revenue growth of 25.60%
Current ratio of 1.31 provides a minimal short-term liquidity buffer
Strong analyst target price ($4.10) suggesting high speculative potential
Positive Q/Q revenue growth trend
Operating in the high-demand Medical Devices industry

Key Risks

Negative book value (P/B -3.87) indicating liabilities exceed assets
Extreme operating losses with an operating margin of -931.58%
Severe financial health deterioration (Piotroski 1/9)
Exorbitant valuation relative to sales (P/S 46.34)
Consistent failure to meet earnings expectations (0/4 beats in last 4 quarters)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
5
Future
40
Past
20
Health
10
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Negative Equity, Piotroski F-Score 1/9, Extreme Operating Margin Loss, Revenue Growth
Confidence
90%
Value
5/100

Ref P/E N/A, P/S 46.34, P/B -3.87

Positives
No standout positives identified.
Watchpoints
  • P/S ratio of 46.34 is extreme
  • Negative Price/Book ratio
  • No Graham Number possible due to negative earnings
Future
40/100

Ref Revenue Growth 25.60%

Positives
  • Revenue growth is steady at ~25%
  • Analyst targets are aggressively bullish
Watchpoints
  • Earnings misses are chronic
  • No clear path to profitability given current margins
Past
20/100

Ref 5Y Change -89.1%, Earnings Track Record

Positives
  • Recent 1-week price recovery
Watchpoints
  • 5-year price decline of 89.1%
  • Consistent earnings surprises to the downside
Health
10/100

Ref Piotroski F-Score, ROE, Debt/Equity

Positives
  • Current ratio above 1.0
Watchpoints
  • Piotroski F-Score 1/9
  • Debt/Equity of 2.36
  • Negative ROE of -710.60%
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • Zero payout capacity

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.28
Analyst Target
$4.1
Upside/Downside
+220.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for LUCD and closest competitors.

Updated 2026-04-13
LUC
Lucid Diagnostics Inc.
Primary
5Y
-89.1%
3Y
-5.9%
1Y
+7.6%
6M
+8.5%
1M
-6.6%
1W
+13.3%
CVR
CVRx, Inc.
Peer
5Y
-70.1%
3Y
-7.4%
1Y
-27.5%
6M
-4.1%
1M
+6.5%
1W
-11.5%
MGN
MacroGenics, Inc.
Peer
5Y
-88.9%
3Y
-46.5%
1Y
+173.2%
6M
+111.6%
1M
+15.7%
1W
+9.1%
MEN
Jyong Biotech Ltd.
Peer
5Y
-72.4%
3Y
-72.4%
1Y
-72.4%
6M
-95.0%
1M
+40.9%
1W
+13.0%
MDW
MediWound Ltd.
Peer
5Y
-51.4%
3Y
+35.6%
1Y
+6.4%
6M
-3.1%
1M
+6.5%
1W
+6.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-7.11
PEG Ratio
N/A
P/B Ratio
-3.87
P/S Ratio
46.34
EV/Revenue
55.77
EV/EBITDA
-5.38
Market Cap
$218.06M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -931.58%
Gross Margin -41.73%
ROE -710.6%
ROA -87.2%

Growth

Revenue and earnings growth rates

Revenue Growth +25.6%
Earnings Growth N/A
Q/Q Revenue Growth +25.65%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
2.36
High debt
Current Ratio
1.31
Good
Quick Ratio
1.27
Good
Cash/Share
$0.21

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
-23.7%
Op. Margin
-931.6%
Net Margin
-1081.5%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
2.70x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12
$N/A
2026-03-26
$-0.1
-15.4% surprise
2025-11-12
$-0.1
-15.4% surprise
2025-08-13
$-0.1

Healthcare Sector Comparison

Comparing LUCD against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-710.6%
This Stock
vs
-86.0%
Sector Avg
+726.3% (Excellent)
Debt to Equity
2.36
This Stock
vs
3.51
Sector Avg
-32.7% (Less Debt)
Revenue Growth
25.6%
This Stock
vs
90.15%
Sector Avg
-71.6% (Slower)
Current Ratio
1.31
This Stock
vs
3.67
Sector Avg
-64.2% (Weaker)

Similar Companies

Peer comparison within the same industry

LUCD Lucid Diagnostics Inc.
BEARISH
Mkt Cap
$218M
P/E
-
ROE
-710.6%
Price
$1.28
CVRX CVRx, Inc.
BEARISH
Mkt Cap
$220M
P/E
-
ROE
-96.6%
Price
$8.37
 Compare with LUCD
MGNX MacroGenics, Inc.
BEARISH
Mkt Cap
$221M
P/E
-
ROE
-86.9%
Price
$3.47
 Compare with LUCD
MENS Jyong Biotech Ltd.
BEARISH
Mkt Cap
$212M
P/E
-
ROE
-%
Price
$2.79
 Compare with LUCD
MDWD MediWound Ltd.
BEARISH
Mkt Cap
$227M
P/E
-
ROE
-63.9%
Price
$17.65
 Compare with LUCD

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

SOKOLOV JACQUE J
Director
Stock Award
2026-02-20
123,000 shares
MCGRATH DENNIS M
Chief Financial Officer
Stock Award
2026-02-20
470,000 shares
LAPIDUS STANLEY N
Director
Stock Award
2026-02-20
123,000 shares
PALUMBO JOHN R
Director
Stock Award
2026-02-20
123,000 shares
AKLOG LISHAN
Chief Executive Officer
Stock Award
2026-02-20
2,170,000 shares
COX JAMES L
Director
Stock Award
2026-02-20
123,000 shares
MATHEIS DENNIS
Director
Stock Award
2026-02-20
123,000 shares
WHITE DEBRA JAYNE
Director
Stock Award
2026-02-20
123,000 shares
O'NEIL SHAUN
President
Stock Award
2026-02-20
620,000 shares
GORDON MICHAEL ADAM
General Counsel
Stock Award
2026-02-20
300,000 shares
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
5 analysts
Ascendiant Capital
2026-04-09
Maintains
Buy Buy
BTIG
2026-03-30
reit
Buy Buy
Needham
2026-03-26
reit
Buy Buy
Ascendiant Capital
2025-12-10
Maintains
Buy Buy
Needham
2025-11-13
reit
Buy Buy

Past News Coverage

Recent headlines mentioning LUCD from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile